glp-1 and parkinson's disease disease(PD)is pathologically characterized by abnormal accumulation of α-synuclein fibers(Lewy bodies) in the substantia nigra other brain regions.🧠Triple-hit hypothesis of gut microbiota in PD.(Blue pathway)👉🏻First,Akkermansia,which Are GLP-1 diabetes drugs like

NICE approved semaglutide (Wegovy) for weight management in specialist NHS weight management services in 2023 (TA875), but availability is limited to patients with: BMI 35 kg/m with at least one weight-related comorbidity, or BMI 30 kg/m with exceptional circumstances Lower BMI thresholds apply for people from some minority ethnic groups (typically 27.5 kg/m) Participation in a specialist weight management programme Treatment limited to a maximum of 2 years Access varies by region due to local integrated care board (ICB) implementation decisions and limited NHS specialist service capacity

This excess water softens the stool and stimulates bowel movements, providing effective constipation relief

There is trial evidence to suggest that semaglutide is effective, and it is licensed in the US and UK for use in overweight adults

2024;35 doi: 10.1016/j.jcte.2024.100333

Were not always successful, and we do make mistakes, but zoom out far enough, and were doing a remarkably good job (Im writing, youre reading this, and were not in a cave)

Gradual dose escalation over 812 weeksrather than rapid titrationgives your digestive system time to adjust and helps separate treatment-related effects from baseline post-cholecystectomy complaints